If the MHRA approved it, why will the NHS not prescribe it?

Because those are different questions. The MHRA licenses on safety and efficacy; NICE decides funding on cost-effectiveness, in a separate appraisal that comes afterwards.

A quality-adjusted life year, combining length and quality of life into one measure so treatments across different conditions can be compared on cost per unit of benefit.

Does a positive NICE recommendation mean immediate availability?

No. Implementation follows the recommendation, and obesity medicines have typically come with eligibility restrictions and service requirements.

Research & Regulatory News

How NICE Decides Whether the NHS Funds a Medicine

JMWritten & reviewed by Jack Muncaster · Founder, UK PeptidesLast reviewed 2026-08-233 cited sources

An MHRA marketing authorisation establishes that a medicine is safe, effective and of adequate quality. It says nothing about whether the NHS will pay for it. That is decided separately by NICE, which assesses cost-effectiveness, and for obesity medicines the size of the eligible population makes those appraisals unusually difficult.

Key facts

MHRA decides: Safety, efficacy, quality — the licence
NICE decides: Cost-effectiveness — NHS funding
Common metric: Cost per quality-adjusted life year (QALY)
Obesity-specific difficulty: Very large eligible population
Typical outcome: Restricted eligibility or managed access
Orforglipron guidance: Expected 18 November 2026

Two decisions, two bodies, two questions

The MHRA asks whether a medicine works and is safe enough to be sold. NICE asks whether the health benefit it delivers justifies its cost relative to everything else the NHS could spend that money on. A medicine can pass the first comfortably and fail the second, and the gap between the two decisions is often a year or more.

What a QALY is and why it governs the outcome

NICE appraisals are built on cost per quality-adjusted life year, a measure combining how long a treatment extends life with how much it improves the quality of that life. A threshold range is applied as a guide rather than a hard rule. The calculation depends heavily on modelled long-term outcomes, which is where obesity medicines become contentious — the benefit accrues over decades and has to be projected rather than observed.

Why obesity medicines are hard appraisals

The eligible population is enormous. A medicine licensed for BMI of 30 or above, or 27 to 30 with a comorbidity, potentially applies to millions of people in England alone. Even a modest cost per patient becomes a very large aggregate budget impact, and budget impact is assessed separately from cost-effectiveness. This is why previous incretin appraisals have produced tightly restricted eligibility, specialist-service requirements or managed-access agreements rather than open prescribing.

The discontinuation problem inside the model

Cost-effectiveness modelling has to account for what happens when treatment stops, and the evidence there is unambiguous: substantial regain follows cessation across the class. A model assuming sustained benefit after stopping produces a very different answer from one assuming most of the reduction is lost. This is one reason maintenance-dosing trial data matter to funding decisions as much as to clinicians.

What to expect in November

Guidance on orforglipron is expected on 18 November 2026. Possible outcomes range from a recommendation with restricted eligibility, through managed access, to a negative recommendation. A positive recommendation does not produce immediate prescribing either — implementation follows, which is why NHS availability before 2027 looks unlikely even in the favourable case.

Extended research context

The Research & Regulatory News deep dive

Deep dive: why 2026 was the year the incretin field split in two

For a decade every meaningful GLP-1 medicine was a peptide, and every one of them was injected. 2026 broke that pattern in both directions at once. In August the MHRA authorised orforglipron, a small molecule with no peptide bonds that works as an ordinary daily tablet. Three months earlier, retatrutide's TRIUMPH-1 reported a 28.3% mean weight reduction — the largest figure yet from a single molecule, and achievable only with a peptide capable of engaging three receptors at once. The field is not converging on one answer; it is separating into a convenience track and a magnitude track, and those tracks have different chemistry.

Deep dive: what a marketing authorisation actually means

An authorisation is granted to a specific product, in a specific formulation, for a specific indication, by a specific regulator. It is not a statement about a compound class and it does not transfer. Orforglipron being licensed in the UK tells you nothing about the legal or regulatory status of any other incretin, and nothing at all about compounds that remain investigational. Authorisation is also separate from funding: a licensed medicine is not automatically available on the NHS, which requires a further NICE appraisal.

Deep dive: reading trial results without being misled

Headline percentages are the least transferable part of a trial. A figure is only meaningful alongside its population, its duration, its comparator and its dropout rate. TRIUMPH-1's 28.3% came from an 80-week study in a relatively uncomplicated obesity population; TRIUMPH-3's 22.6% came from adults with severe obesity and established cardiovascular disease, and the gap between those two numbers is mostly population, not potency. Discontinuation rates deserve the same attention as efficacy: 11.3% of the TRIUMPH-1 12 mg arm stopped due to adverse events against 4.9% on placebo, and that figure is routinely dropped from summaries.

Research applications

▸Tracking regulatory status of investigational incretin compounds
▸Understanding the difference between authorisation, NICE appraisal and NHS availability
▸Comparing peptide and non-peptide receptor agonist pharmacology
▸Interpreting Phase 3 topline releases before peer-reviewed publication
▸Verifying trial identity against ClinicalTrials.gov registrations

Handling checklist

✓Check the compound named in a trial registration matches the compound being discussed
✓Confirm the NCT identifier resolves to the acronym being cited
✓Read topline press releases as preliminary until peer-reviewed publication
✓Separate the trial population from the headline percentage before comparing studies
✓Treat authorisation in one jurisdiction as saying nothing about status in another

Common research-handling mistakes

Learnt from thousands of researcher orders across our UK labs.

✗ Treating a positive Phase 3 as approval

Fix: Filing begins a review that commonly takes a year or more and can end in a request for more data.

✗ Comparing weight-reduction percentages across different trials

Fix: Population, duration and comparator differ; the numbers are not interchangeable.

✗ Assuming one incretin's approval legitimises another compound

Fix: Authorisations are product-specific and do not transfer between compounds.

✗ Citing a TRIUMPH number without checking the NCT identifier

Fix: Verify against ClinicalTrials.gov — the numbering has been widely misreported.

✗ Reading research material as an alternative to a licensed medicine

Fix: Research material is supplied for laboratory use only and is not a substitute for anything prescribed.

Continue researching

Peer-reviewed guides, comparators and matched reference materials.

Frequently asked questions

If the MHRA approved it, why will the NHS not prescribe it?: Because those are different questions. The MHRA licenses on safety and efficacy; NICE decides funding on cost-effectiveness, in a separate appraisal that comes afterwards.
What is a QALY?: A quality-adjusted life year, combining length and quality of life into one measure so treatments across different conditions can be compared on cost per unit of benefit.
Does a positive NICE recommendation mean immediate availability?: No. Implementation follows the recommendation, and obesity medicines have typically come with eligibility restrictions and service requirements.

Primary sources & clinical trials

Peer-reviewed research and registered trials from PubMed, ClinicalTrials.gov, PubChem, FDA and NIH. All links open in a new tab and point to the primary source, so every claim can be verified at origin.

Written and reviewed by

Jack Muncaster · Founder, UK Peptides

Jack founded UK Peptides in Manchester after repeatedly receiving research compounds with missing or recycled paperwork. He is responsible for supplier selection, batch release decisions and the content published in this research library. Every article here is sourced to primary literature and every product page to a signed third-party certificate.

How we write and check this content Report a factual error in this article

More Research & Regulatory News articles

Popular across the research hub

One flagship guide from every other research category — keep exploring.

← Back to Forum